This SP for BNO is quite strange. If one assumes the company has cash of about $40m then the enterprise value is about $85m (at this SP). That looks to be very low when it is compared to a number of other biotechs. It has the hallmarks of a buying opportunity now that we are getting close to hearing the results of the 210 trial.
This SP for BNO is quite strange. If one assumes the company has...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)